ArticleCureus2021
Adalimumab-Induced Thrombocytopenia in a Patient With Hidradenitis Suppurativa.
Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Adalimumab-Induced Thrombocytopenia: A Case Report of Drug-Induced Thrombocytopenia.Case reports in hematology · 2025Article
- Case Report: Severe thrombocytopenia induced by adalimumab in rheumatoid arthritis: A case report and literature review.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adalimumab-induced thrombocytopenia is a rarely occurring condition that may present with hemorrhagic manifestations. This report describes a case of a patient who presented with severe, symptomatic thrombocytopenia while on adalimumab for the treatment of hidradenitis suppurativa. The patient responded to treatment with steroids, intravenous immunoglobulin (IVIG), and platelet transfusion, in addition to discontinuation of adalimumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.